Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796249 | 0.81 | FAAH (0.39) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL11208899 | 0.80 | HIF1A (0.41) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL8664394 | 0.75 | SORD (0.43) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL24796169 | 0.75 | SORD (0.43) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL85415 | 0.75 | CA12 (0.41) | HIF1ASMN1; SMN2TP53 | |
| SCHEMBL890241 | 0.73 | HIF1A (0.42) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL11210561 | 0.73 | HIF1A (0.45) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL24795818 | 0.72 | CA12 (0.44) | HIF1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL20992668 | 0.72 | CA12 (0.39) | HIF1ASMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL17150578 | 0.72 | CA12 (0.39) | HIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202991-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230202991-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-06-29 | — | — | US | disclosed |
| EP-4180090-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-115836058-A | Benzisoxazole derivatives | 住友制药株式会社 | 2023-03-21 | — | — | CN | disclosed |
| US-20220289694-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-15 | — | — | US | disclosed |
| WO-2022009863-A1 | BENZISOXAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2022-01-13 | — | — | WO | disclosed |
| US-5786374-A | FUNGICIDES, MICROBIOCIDES | NOVARTIS CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| CN-1162308-A | Benzisoxazole derivatives and pesticidal compositions containing them | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | CN | disclosed |
| EP-0789692-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | Novartis AG (CH) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014305-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202991-A1 | BENZISOXAZOLE DERIVATIVE | HDAC3, GABRA5, HDAC2 | HIF1A 2241/4885SMN1; SMN2 1379/4885TP53 4728/4885 |
| US-20220289694-A1 | BENZISOXAZOLE DERIVATIVE | HDAC3, GABRA5, HDAC2 | HIF1A 2241/4885SMN1; SMN2 1379/4885TP53 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.